Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million (approximately 521.
Search results for "platform technology"
Turning Off Cancer Signals: New Precision Drug Stops Tumors Without Harming Healthy Cells
South Korean researchers have developed a novel anticancer approach capable of selectively turning off specific cellular "switches" that drive tumor...
Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009
Kyungdong Pharmaceutical announced Sept. 2 that it has submitted an investigational new drug application to the...
Skin Aging Is More Than Collagen Loss: GC Green Cross Wellbeing Unveils Next-Gen ECM Booster in the Philippines
When skin begins to sag and lose its glow, many people attribute the change solely to declining collagen.
Hansol Hospital Reaches 200 Single-Port Robotic Surgeries in 8 Months
Hansol Hospital, a colorectal specialty hospital designated by the Ministry of Health and Welfare, announced Sept.
Bundang CHA Hospital Develops Bone-Regeneration Scaffold Powered by Lactic Acid Signaling
When a fracture is severe or involves substantial bone loss, the body's natural regenerative capacity often falls short.
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
AI Consortium Launches 7.5 Billion Won Project to Personalize Chronic Pain Rehab for Older Adults
"My knee hurts constantly," an older patient might tell their doctor. Yet in many cases, diagnostic imaging like X-rays...
Regenerative Technique Aims to Solve Rotator Cuff Re-Tears by Rebuilding the Tendon-Bone Junction
When surgeons reattach a torn shoulder tendon to the bone, a frustrating setback often occurs over time: the repair...
Samyang Biopharm’s NanoReady Delivers 20x mRNA Payload for Personalized Cancer Vaccines
Samyang Biopharm announced on the 20th that nonclinical study results for its proprietary gene delivery platform,...